

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	ROTH et al	Examiner:	Sitton, Jehanne S.
Serial No.:	10/661,996	Group Art Unit:	1634
Filed:	September 11, 2003	Docket:	SEQ-4038-UT
Conf. No.:	9006		
Title:	METHODS FOR IDENTIFYING RISK OF MELANOMA AND TREATMENTS THEREOF		

---

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication. Applicant also brings to the Office's attention the existence of the following recently abandoned or co-pending related applications: (1) application no. 10/703,817 filed November 6, 2003, published as US2005-0118117 A1 on June 2, 2005 (Attorney Docket: SEQ-4061-UT, Examiner Sarae L. Bausch), (2) application no. 10/703,789 filed November 6, 2003, published as US2005-0064440 A1 on March 24, 2005, (Attorney Docket: SEQ-4063-UT, Examiner Examiner Sarae L. Bausch), (3)

INFORMATION DISCLOSURE STATEMENT

Serial No.: 10/661,966

Filing Date: September 11, 2003

Title: METHODS FOR IDENTIFYING RISK OF MELANOMA AND TREATMENTS THEREOF

Page 2

Dkt: SEQ-4038-UT

application no. 10/704,513 filed November 6, 2003, published as US2005-0170500 A1 on August 4, 2005 (Attorney Docket: SEQ-4062-UT, Examiner Sarae L. Bausch), and (4) application no. 10/840,590 filed May 5, 2004, published as US2005-0233341 A1 on October 20, 2005 (Attorney Docket: SEQ-4061-CP, Examiner Sarae L. Bausch).

The listed documents are being submitted in compliance with 37 CFR § 1.97(c), after the first Office action on the merits but before a final Office action. If any additional fees are due, please contact the undersigned attorney at (858) 623-9470. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: March 19, 2007

By: /Bruce Grant/

Bruce Grant  
Reg. No. 47608  
Attorney for Applicants  
BioTechnology Law Group  
Customer No. 47328  
Telephone: (858) 623-9470

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)**Complete if Known**

<b>Application Number</b>	10/661,966
<b>Filing Date</b>	September 11, 2003
<b>First Named Inventor</b>	ROTH, Richard B.
<b>Group Art Unit</b>	1634
<b>Examiner Name</b>	SITTON, Jehanne S.

Sheet 1 of 1

Attorney Docket No: SEQ-4062-UT

**US PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
---------------------	-----------------------	---------------------	------------------	-------------------------------------------------	---------------------------------------------------------------------------

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
---------------------	-----------------------	---------------------	------------------	-------------------------------------------------	---------------------------------------------------------------------------	----------------

**OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A1.	Cantor & Smith, <i>Genomics: The Science and Technology Behind the Human Genome Project</i> , 1999, John Wiley & Sons, Inc., New York, pages 164-167, 170-173, 180-181 and 190-193.	
	A2.	Cantor & Nelson, "Haplotyping in biomedicine – practical challenges," <i>Nature Biotech</i> 23: 21-22 (2005).	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-S400)

\* EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP § 905. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language. Translation is attached.